3SHANDER A, CAPPELLINI M D, GOODNOUGH L m Iron overload and toxicity: the hidden risk of ultiple blood transfusions [J]. Vox Sang, 2009,97 185-197.
4TAKATOKU M,UCHIYAMA T, OKAMOTO S, et al. Retrospective nationwide survey of Japanese pa tients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morhidity/mortality[J]. Eur J Haematol, 2007,78 487--494.
5LEE J W,YOON S S,SHEN Z X,et al. Iron chelation therapy with deferasirox in patients with aplastic ane mia..a Subgroup analysis of 116 patients from the EP IC trial[J]. Blood, 2010,116 : 2448-- 2454.
6DE GROOTE P, DELOUR P, MOUQUET F, et al. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection action improvement and impact on prognosis [J].Am Heart J,2007,154:589--595.
7CHEN X H,SCHOLL T O,STEIN T P. Association of elevated serum ferritin 1 evels and the risk of gesta tional diabetes mellitus in pregnant women[J]. Diabe tes Care,2006,29 : 1077- 1081.
8MALCOVATI L, PORTA M G, PASCUTTO C, ct al. Prognostic factors and life expectancy in myelodys plastic syndromes classified according to WHO crite ria:a basis for clinicaldecision making[J]. J Clin On col,2005,23:7594- 7603.
9NICOLAS G, VIATTE L, BENNOUN M, et al. Hepcidin,a new iron regulatory peptide[J]. Blood Cells Mol Dis,2002,29:327--333.
10WEINSTEIN D A, ROY C N, FI.EMING M D et al. Inappropriate expression of hepcidin is associated with iron refractory anemia:implication for the anemia of chronicisease[J].Blood,2002,100:3776- 3781.
二级参考文献9
1Deborah CS,Geukes-Foppen M,Barry K,et al.Practical implications of liver and heart iron load assessment by T2 * -MRI in children and adults with transfusion-dependent anemias[J].Am J Hematol,2008,83(10):781 -783.
2Mamtani M,Kuikarni H.Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalsssaemia:a systematic review and meta-analysis[J].Br J Haemato1,2008,141(6):882 -890.
3Borgna-Pignatti Co Cappellini MD,De Stefano P,et al.Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major[J].Blood,2006,107 (9):3733 -3737.
4Malcovati L,Porta MG,Psscutto C,et al.Prognostic factors and life expectancy in myeledysplastie syndromes classified sccording to WHO criteria:a basis for clinical decision making[J].J Clin Onol,2005,23 (30):7594-7603.
5Bennett JM.Consensus statement on iron overload in myeiodysplastic syndromes[J].Am J Hematol,2008,83(11):858 -861.
6Tanner MA,Galanello R,Dessi C,et al.Myocardial iron loading in patients with thalsssemia major on deferoxamine chelation[J].J Cardiovasc Magn Re,on,2006,8 (3):543-547.
7Borgna-Pignatti C,Cappellini MD,De Stefano P,et al.Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalsssemia major[J].Blood,2006,107(9):3733 -3737.
8Piga A,Galanello R,Fomi GL,et al.Randomized phase Ⅱ trial of deferasirox,a once-daily,orally-administered iron chelator,in comparison to deferoxamine in thalassemia patients with transfusional iron overload[J].Haematolngica,2006,91 (7):873-880.
9Choudhry VP,Naithani R.Current status of iron overload and chelation with dcferssirox[J].Indian J Pediatr,2007,74 (8):759 -764.
7Christiansen H,Saile B,Hermann RM,et al.Increase ofhepcidin plasma and urine levels is associated with acuteproctitis and changes in hemoglobin levels in primary ra-diotherapy for prostate cancer[J].J Cancer Res Clin Oncol,2007,133(5):297-304.
8Kattamis A,Papassotiriou I,Palaiologou D,et al.The ef-fects of erythropoetic activity and iron burden on hep-cidin expression in patients with thalassemia major [J],Haematologica,2006,91(6):809-812.
9Papanikolaou G,Tzilianos M,Christakis Jl,et al.Hep-cidin in iron overload disorders[J].Blood,2005,105(10):4103-4105.
10Ruchala P,Nemeth E.The pathophysiology and pharma-cology of hepcidin [J].Trends Pharmacol Sci,2014,35(3):155-161.
